165 related articles for article (PubMed ID: 35429141)
1. Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function.
Dong J; Zhu D; Chen M; Wang T; Gao Y; Liu W
Thorac Cancer; 2022 May; 13(10):1513-1524. PubMed ID: 35429141
[TBL] [Abstract][Full Text] [Related]
2. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of flavokawain-B flavonoid in gemcitabine-resistant lung cancer cells are mediated via mitochondrial-mediated apoptosis, ROS production, cell migration and cell invasion inhibition and blocking of PI3K/AKT Signaling pathway.
Hua R; Pei Y; Gu H; Sun Y; He Y
J BUON; 2020; 25(1):262-267. PubMed ID: 32277640
[TBL] [Abstract][Full Text] [Related]
4. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
Yang H; Li H; Lu S; Shan S; Guo Y
Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
[TBL] [Abstract][Full Text] [Related]
5. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
6. Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer.
Wu S; Zhao Q; Liu S; Kuang J; Zhang J; Onga A; Shen Y; Wang J; Sui H; Ni L; Ye Y; Tu X; Le HB; Zheng Y; Cui R; Zhu W
Int J Oncol; 2024 Aug; 65(2):. PubMed ID: 38873997
[TBL] [Abstract][Full Text] [Related]
7. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
9. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
10. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
12. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
14. (+)-Usnic Acid Induces ROS-dependent Apoptosis via Inhibition of Mitochondria Respiratory Chain Complexes and Nrf2 Expression in Lung Squamous Cell Carcinoma.
Qi W; Lu C; Huang H; Zhang W; Song S; Liu B
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013250
[TBL] [Abstract][Full Text] [Related]
15. Davanone terpenoid inhibits cisplatin-resistant acute myeloid leukemia cancer cell growth by inducing caspase-dependent apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and targeting PI3K/AKT/MAPK signalling pathway.
Xiao Y; Deng T; Wang D
J BUON; 2020; 25(3):1607-1613. PubMed ID: 32862611
[TBL] [Abstract][Full Text] [Related]
16. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
[TBL] [Abstract][Full Text] [Related]
17. Propofol and Sevoflurane Alleviate Malignant Biological Behavior and Cisplatin Resistance of Xuanwei Lung Adenocarcinoma by Modulating the Wnt/β-catenin Pathway and PI3K/AKT Pathway.
Quan Y; Li S; Wang Y; Liu G; Lv Z; Wang Z
Anticancer Agents Med Chem; 2022; 22(11):2098-2108. PubMed ID: 35152870
[TBL] [Abstract][Full Text] [Related]
18. [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer].
Zhang Y; Lu H; Xu G
Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):635-42. PubMed ID: 25130971
[TBL] [Abstract][Full Text] [Related]
19. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
